EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium

Ann T Ma iD, Andrew S Allegretti, Giuseppe Cullaro iD, Tianqui Ouyang, Sumeet K Asrani iD, Raymond T Chung, Eric M Przybyszewski, Robert M Wilechansky, Jevon E Robinson, Pratima Sharma, Douglas A Simonetto, Prasun Jalal und 10 weitere

Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (6) · 778-786

DOI: 10.1111/apt.18159 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 15.07.2024. Verfasst von Ann T Ma und 21 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Acute Kidney Injury, Hepatitis, Alcoholic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Association for the Study of Liver Diseases Clinical, Translational, and Outcomes Research Award, MGH Research Scholars Program, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims The development of acute kidney injury (AKI) in the setting of alcohol‐associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown.

Methods

Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non‐AH groups.

Results

A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End‐stage Liver Disease‐Sodium (MELD‐Na) scores on admission. AKI phenotypes significantly differed between groups ( p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90‐day cumulative incidence of death (45% [95% CI: 39%–51%] vs. 38% [95% CI: 35%–40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90‐day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03–1.50], p = 0.024), but was not significant when adjusting for MELD‐Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90‐day mortality (sHR: 1.82 [95% CI: 1.16–2.86], p = 0.009).

Conclusions

Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90‐day mortality than those without AH, but this may have been driven by higher MELD‐Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryHepatitis, AlcoholicHumansMaleFemaleMiddle AgedRetrospective StudiesPrognosisAdultAgedSeverity of Illness IndexLiver CirrhosisRenal Replacement TherapyRisk FactorsUnited States

Autor:innen und Institutionen

  • Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
  • Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Gastroenterology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Baylor University Medical Center, Dallas, Texas, USA.
  • Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Internal Medicine, University of Michigan Health, Ann Arbor, Michigan, USA.

ORCID-Profile: Ann T Ma, Giuseppe Cullaro, Sumeet K Asrani, Nneka N Ufere, Kavish R Patidar

Förderung

  • American Association for the Study of Liver Diseases Clinical, Translational, and Outcomes Research Award
  • MGH Research Scholars Program
  • NIDDK NIH HHS
  • NIAAA NIH HHS
  • Merck
  • Roche
  • Gilead
  • Bristol-Myers Squibb

Zitieren

APA

Ma, A. T., Allegretti, A. S., Cullaro, G., Ouyang, T., Asrani, S. K., Chung, R. T., Przybyszewski, E. M., Wilechansky, R. M., Robinson, J. E., Sharma, P., Simonetto, D. A., Jalal, P., Orman, E. S., Wadei, H. M., St Hillien, S. A., Saly, D., Ufere, N. N., Dageforde, L. A., Regner, K. R., …, & from the HRS Harmony Consortium (2024). Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics, 60(6), 778-786. https://doi.org/10.1111/apt.18159

Vancouver

Ma AT, Allegretti AS, Cullaro G, Ouyang T, Asrani SK, Chung RT, et al. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics. 2024;60(6):778-786. doi:10.1111/apt.18159

BibTeX
@article{Ma2024,
  author = {Ma, Ann T and Allegretti, Andrew S and Cullaro, Giuseppe and Ouyang, Tianqui and Asrani, Sumeet K and Chung, Raymond T and Przybyszewski, Eric M and Wilechansky, Robert M and Robinson, Jevon E and Sharma, Pratima and Simonetto, Douglas A and Jalal, Prasun and Orman, Eric S and Wadei, Hani M and St Hillien, Shelsea A and Saly, Danielle and Ufere, Nneka N and Dageforde, Leigh Anne and Regner, Kevin R and Belcher, Justin M and Patidar, Kavish R and from the HRS Harmony Consortium, from the HRS Harmony Consortium},
  title = {Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {6},
  pages = {778--786},
  doi = {10.1111/apt.18159}
}
Kostenlos starten →